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Background: Paediatric low-grade gliomas (LGGs) encompass a heterogeneous set of tumours of different histologies,
site of lesion, age and gender distribution, growth potential, morphological features, tendency to progression and
clinical course. Among LGGs, Pilocytic astrocytomas (PAs) are the most common central nervous system (CNS) tumours
in children. They are typically well-circumscribed, classified as grade I by the World Health Organization (WHO), but
recurrence or progressive disease occurs in about 10-20% of cases. Despite radiological and neuropathological features
deemed as classic are acknowledged, PA may present a bewildering variety of microscopic features. Indeed, tumours
containing both neoplastic ganglion and astrocytic cells occur at a lower frequency.
Methods: Gene expression profiling on 40 primary LGGs including PAs and mixed glial-neuronal tumours comprising
gangliogliomas (GG) and desmoplastic infantile gangliogliomas (DIG) using Affymetrix array platform was performed.
A biologically validated machine learning workflow for the identification of microarray-based gene signatures was
devised. The method is based on a sparsity inducing regularization algorithm l1l2 that selects relevant variables and
takes into account their correlation. The most significant genetic signatures emerging from gene-chip analysis were
confirmed and validated by qPCR.
Results: We identified an expression signature composed by a biologically validated list of 15 genes, able to
distinguish infratentorial from supratentorial LGGs. In addition, a specific molecular fingerprinting distinguishes the
supratentorial PAs from those originating in the posterior fossa. Lastly, within supratentorial tumours, we also identified
a gene expression pattern composed by neurogenesis, cell motility and cell growth genes which dichotomize mixed
glial-neuronal tumours versus PAs. Our results reinforce previous observations about aberrant activation of the
mitogen-activated protein kinase (MAPK) pathway in LGGs, but still point to an active involvement of TGF-beta
signaling pathway in the PA development and pick out some hitherto unreported genes worthy of further
investigation for the mixed glial-neuronal tumours.
Conclusions: The identification of a brain region-specific gene signature suggests that LGGs, with similar pathological
features but located at different sites, may be distinguishable on the basis of cancer genetics. Molecular fingerprinting
seems to be able to better sub-classify such morphologically heterogeneous tumours and it is remarkable that mixed
glial-neuronal tumours are strikingly separated from PAs.
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Primary intra-axial paediatric low grade tumours include
pilocytic astrocytoma (PA), pilomyxoid astrocytoma,
diffuse fibrillary astrocytoma (FA), ganglioglioma (GG),
desmoplastic infantile ganglioglioma (DIG), desmoplastic
infantile astrocytoma (DIA) and dysembryoplastic neuro-
epithelial tumour [1]. For brevity, they will be thereafter
defined LGG.
PA is the most common central nervous system
(CNS) tumour, representing approximately 21-23% of
all primary brain tumours in children [2]. It is typically a
well-circumscribed, contrast-enhancing astrocytic neoplasm
with prolonged overall survival and high complete
remission rates [3]. PA arises most commonly in the cere-
bellum, but can be found anywhere, including the cerebral
hemispheres, thalamus and hypothalamus, brainstem, optic
pathways, and spinal cord [3,4].
Reflecting the generally slow growth and low proliferative
potential of LGGs, complete surgical resection is the
preferred therapeutic choice. Unfortunately, gross total
resection is not attainable in many of these tumours that
are centrally located which, in about 10 to 20% of the
cases, despite adjuvant treatment, tend to recur or show
progressive growth [5,6]. Most importantly, rare examples
of PA undergo malignant transformation, even if completely
resected [7,8].
Despite radiological and neuropathological features
deemed as classic are acknowledged, PA may present a
bewildering variety of microscopic features, including a
wide range of tissue patterns, most of which may be
found within the same lesion. It is worth remembering that
both normal and neoplastic astrocytes exhibit molecular
and functional heterogeneity [9-13].
The tumours containing both neoplastic ganglion
and astrocytic cells are rare, representing less than an
hundredth of the tumours of CNS and its coverings.
Such tumours, which belong to the neuronal and mixed
glial-neuronal tumours of the WHO classification and
corresponding to grade I, comprise gangliogliomas (GG),
and gangliogliomas with desmoplasia, i.e. desmoplastic
infantile gangliogliomas (DIG) both typically arising from
the telencephalon [2]. The differential diagnosis may be
difficult due to small biopsy size. Moreover, the glial
component of a ganglioglioma may be pilocytic looking
(this is as much as to say that a pilocytic morphology is
considered completely acceptable in a ganglioglioma). Lack
of specific immunohistochemical, cytogenetic, or molecular
markers increases difficulties in classification.
The expanding utilization of high-throughput technolo-
gies to study paediatric brain tumours will likely change
how they are both classified and treated henceforward [5,6].
In this field, the use of microarrays has been expanding
exponentially to several areas such as genetic screening,
safety assessment and diagnostics [14], but repeatabilityof published microarray studies is apparently limited
[15,16]. In the neuro-oncological context, a LGG
genotype-phenotype correlation still remains an open
problem [17,18]. Gene signatures able to classify LGGs in
accordance with clinical and biological features were pro-
vided [9,19-22]. Nevertheless, a complete genetic landscape
of paediatric PA is still missing and the specific molecular
signatures able to correlate their phenotype (brain sites and
heterogeneous histotypes) to their genotype still remain to
be studied in depth.
Keeping this in mind, we aimed to identify a molecular
fingerprinting able to reflect different histotypes and
brain region in LGGs. In particular, the study addressed
three different biological questions: (1) characterize
supratentorial vs. infratentorial LGGs, (2) identify a specific
characterization for the PAs based upon site of lesion, and
(3) discriminate, within supratentorial neoplasms, mixed
glial-neuronal tumours vs. PAs.
This relatively simple, albeit fraught with meaning, goal
gave us the opportunity to develop a robust and validated
experimental workflow, paving the way for future studies,
whose goal will be the identification of gene fingerprints
explicitly correlated to clinical parameters.
Methods
We adopted a biologically validated method to identify
reliable and predictive gene expression signatures on
tumour data. The pipeline, represented in Figure 1, is a
supervised machine learning workflow consisting in
3 main consecutive phases: case selection and tumour spe-
cimen processing, unbiased l1l2 feature selection framework
with functional characterization of the gene signature,
and real-time quantitative reverse transcription-PCR
(qPCR). Detailed description of the pipeline is reported in
Additional file 1.
Case selection and tumour processing
A series (dataset 1) of 40 paediatric primary LGGs who
underwent surgery from 1991 to 2009 at the Neurosurgery
Unit of the Giannina Gaslini Children’s Hospital were
selected and enrolled in the study. The inclusion criteria
were diagnosis of PA or ganglioglioma with or without
desmoplasia, i.e. GG or DIG; the availability of complete
clinical data and fresh frozen tissue specimen with a
tumour cell content of at least 80%, while exclusion criteria
were lack of histological diagnosis and the presence of
extensive dissemination. The cohort included 27 PAs, 12
mixed glial-neuronal tumours (7 GGs and 5 DIGs) and
one FA. Seventeen tumours arose in infratentorial regions,
while 23 were supratentorial. The FA was forced in the first
phase of analysis and partially during the second phase in
order to have an internal control. Only one case was asso-
ciated with a genetic syndrome, namely Neurofibromatosis
type 1 (NF1) [MIM ID #162200]. The male/female
Figure 1 Workflow. This figure depicts the entire workflow consisting in several computational and biological procedures. The three main
phases are indicated as Phase 1 (data preparation), Phase 2 (statistical analysis and candidate gene list identification) and Phase 3 (validation).
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months to 17 years). The main clinical-pathological
features are summarized in Table 1. The sections
were reviewed by the local neuropathologist (P.N.)
and the tumours were classified according to the
WHO classification [3]. The sets of samples are formed to
precisely answer the biological questions of interest.
Moreover, the sets were made the more homogeneous
possible in order to minimize the undesiderable effects of
the inter-tumoural genetic differences due to the intrinsic
constitutional variations among individuals.
Total RNA was extracted from serial frozen sections
of tumour tissue by using the TRIzol reagent combined
with silica column purification system (Invitrogen,
Carlsbad, CA). Quantification and quality assurance
were performed using the NanoDrop spectrophotometer
(NanoDrop Technologies Wilmington, Delawere USA)
and the Agilent 2100 bioanalyzer (Agilent Technologies,
Waldbronn, Germany), respectively. Double-stranded
cDNA were processed according to the Affymetrix
GeneChip Expression Analysis Technical Manual
(Affymetrix, Santa Clara, CA). Microarray data for 40 LGG
samples was generated with Affymetrix HG-U133Plus2.0
arrays (Affymetrix, Santa Clara, CA). Gene expressions
were extracted from the .CEL files and normalized using
the Robust Multichip Average method [23] by runningan R [24] script, based on the aroma package [25]. The
dataset for the microarray experiment was uploaded
in the Gene Expression Omnibus public repository
at National Center for Biotechnology Information
[accession number GSE28238].
Written informed consent was obtained from all the
patients’parents or guardians and the local Ethics
Committee for human studies approved the research.
Unbiased l1l2 feature selection framework
The feature selection method we adopted is a
regularization method capable of selecting subsets of
discriminative genes, namely l1l2 regularization with
double optimization. The algorithm can be tuned to give
a minimal set of discriminative genes or larger sets
including correlated genes. The method is based on
the optimization principle presented in [26] and further
developed and studied in [27,28].
The l1l2 with double optimization algorithm looks for
a linear function (model), whose sign gives the classification
rule that can be used to associate a new sample to one of
the two classes. The output function is a sparse model, i.e.
some input variables (probe-sets) will not contribute to the
final estimator. The algorithm is based on the minimization
of a functional depending on a least square error
term combined with two penalties. The least square
Table 1 Clinical data
ID Age Gender Diagnosis WHO Site
(months) grade
1 35 F PA I Infratentorial
2 30 M PA I Infratentorial
3 29 M PA I Infratentorial
4 38 F PA I Infratentorial
5 37 M PA I Infratentorial
6 42 F PA I Infratentorial
7 16 F PA I Infratentorial
8 46 F PA I Infratentorial
9 41 M PA I Infratentorial
10 33 M PA I Infratentorial
11 143 F PA I Infratentorial
12 82 F PA I Infratentorial
13 165 F PA I Infratentorial
14 48 F PA I Infratentorial
15 67 M PA I Infratentorial
16 149 M PA I Infratentorial
17 36 F PA I Infratentorial
18 161 M PA I Supratentorial
19 104 F PA I Supratentorial
20 176 M PA I Supratentorial
21 153 M PA I Supratentorial
22 108 F PA I Supratentorial
23 188 M PA I Supratentorial
24 128 M PA I Supratentorial
25 32 F PA I Supratentorial
26 5 F PA I Supratentorial
27 108 M PA I Supratentorial
28 171 M FA II Supratentorial
29 11 F DIG I Supratentorial
30 27 F DIG I Supratentorial
31 6 F DIG I Supratentorial
32 6 M DIG I Supratentorial
33 13 M DIG I Supratentorial
34 14 F GG I Supratentorial
35 155 M GG I Supratentorial
36 119 F GG I Supratentorial
37 189 F GG I Supratentorial
38 149 M GG I Supratentorial
39 199 F GG I Supratentorial
40 130 F GG I Supratentorial
For each patient we report the corresponding ID, age at surgery (in months),
gender (F = female, M= male), diagnosis (PA = pilocytic astrocytoma,
FA = diffuse fibrillary astrocytoma, DIG = desmoplastic infantile ganglioglioma,
GG = ganglioglioma and site of lesion. Patient ID24 reported in bold is
associated to the genetic syndrome NF1.
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penalties allows to avoid over-fitting. The role of the two
penalties is different, the l1 term (sum of absolute values)
enforces the solution to be sparse, the l2 term (sum of the
squares) preserves correlation among the variables. The
training for selection and classification requires the choice
of the regularization parameters for both l1l2 regularization
and regularized least squares (RLS) denoted with τ* and λ*,
respectively. In fact model selection and statistical signifi-
cance is performed within two nested K-cross validation
loops as in [29,30]. Being interested in a comprehensive
list of relevant variables we fixed our attention on the
lists obtained with the highest values for the correlation
parameter μ.
The statistical framework described above provides a
set of K lists of selected variables, therefore it is necessary
to choose an appropriate criterion [31] in order to assess a
common list of relevant variables (probe-sets or proteins,
in our case). We based ours on the absolute frequency, i.e.
we decided to promote as relevant variables the most
stable probe-sets across the lists. The threshold we used
to select the final lists was chosen according to the slope
variation of the number of selected genes vs. frequency
(plot not shown), its value being 70%. In this way we
manage to cut out those variables that are not stable
across the cross-validation lists, similarly to the procedure
adopted in [30]. We also visualized the signatures in
heat-map plots and 3d visualizations of classified samples.
Functional characterization of the gene signature
Multiple probe-sets for a gene were collapsed to one
entry per gene, based on the best frequency score.
Non-mapping or non-coding probe-sets were discarded.
The National Institute of Health Database for Annotation,
Visualization and Integrated Discovery (DAVID) web-tool
[32] was used to identify structural, functional, and path-
way categories in the selected list. The analysis also ranked
in detail the Gene Ontology (GO) [33] terms in the
Biological Process (BP) domain including the identified
probe-sets. The functional annotation was performed
using the Expression Analysis Systematic Explorer (EASE)
[34] with structural and functional class data from the
GO, GenBank and UniGene databases, and with pathway
data from Gene Map Annotator and Pathway Profiler
(GenMAPP) [35], the Kyoto Encyclopedia of Genes and
Genomes (KEGG) [36] and the Biocarta [37] databases.
The Exploratory Gene Association Networks (EGAN)
Java desktop application was also used to visualize the
interactions among the selected genes [38].
Real-time quantitative reverse transcription-PCR
Following the same criteria for the case selection, we
chose an additional set of patients (dataset 2), composed
by 14 PAs and 4 mixed glial-neuronal tumours, in order
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genetic signatures emerging from gene-chip analysis. Each
systems were in-house designed by a fine tuning procedure
as described [39]. Specific primers were developed targeting:
ABBA1 [NM 138383], APOD [NM 001647], ARX [NM
139058], CXCL14 [NM 004887], FOSB [NM 001114171],
FOXG1 [NM 005249], GPR17 [NM 001161415], LHX2
[NM 004789], NRXN2 [NM 015080], PTGD2S [NM
000954], SDC3 [NM 014654], SNX22 [NM 024798],
SPOCK1 [NM 004598], TIMP4 [NM 003256] and ZFHX4
[NM 024721]. Primers sequences and the amplification con-
ditions are reported in Additional file 2. Beta actin (ACTB)
[NM 001101], Pyruvate kinase (PKM2) [NM 002654] and
Beta-2-microglobulin (B2M) [NM 004048] were used as the
endogenous control genes for each tumour specimen [39].
Amplifications were performed using an ABI PRISM 7500
HT Sequence Detection System (Applied Biosystems, Foster
City, CA) and primer concentrations were adjusted accord-
ingly to the assays temperature. Validation of each system
was performed using standard curves (SCs) on cDNA
derived from the 1603-MED medulloblastoma cell line [40].
The reproducibility of the calibration curve was ana-
lyzed qPCR efficiencies of each system were calculated as
described [41]. The relative quantification of genes
transcript was performed according to the comparative
method (2-ΔCt), Applied Biosystems User Bulletin no. 2P/
N 4303859) [42,43], using the value emerged by geometric
mean of B2M, PKM2 and ACTB as the normalizer
(Ctref ). Gene expression levels of the 18 candidates
were calculated for each LGG sample by the 2-ΔΔCt
equation using as ΔCtref the median ΔCt value among
all cases. The Minimum Information for Publication
of qPCR Experiments (MIQE) are provided [44].
Statistical validation
Comparisons of the quantitative data of gene expressions
were performed by the Mann–Whitney U test since the
normality and homoscedasticity assumptions were not
fulfilled. Statistical tests were 2-sided, and a p-value less
than 0.05 was considered statistically significant.
We also performed a multivariate data analysis by
employing the algorithm known as Regularized Least
Squares (RLS) [45]. The algorithm is based on the
minimization of a functional depending on a least square
error term combined with a regularization term, i.e., the l2
term (sum of the squares). Similarly to the l1l2 algorithm,
RLS is run in a double nested cross-validation framework
to avoid selection bias.
Results
Biologically validated molecular fingerprint of
infratentorial versus supratentorial LGGs
We conducted a high-resolution analysis of genome-wide
expression patterns on 40 paediatric LGGs, including 17arising in infratentorial and 23 in supratentorial regions
(Table 1), using Affymetrix HG-U133 Plus 2.0 chip-arrays.
To select a list of highly discriminative probe-sets, we
applied the l1l2 selection statistical framework to the
dataset. The system performance was evaluated by its
corresponding cross-validation error, as low as 8%.
The resulting list, reported in Additional file 3, consists of
331 probe-sets, sorted according to their frequency
score and corresponding to the maximum value of the
correlation parameter μ.
The strong discriminative power of the selected
probe-sets is depicted by either a heat-map plot or a
multivariate representation (Figure 2a,b). The FA case was
not classified neither supratentorial nor infratentorial by
the l1l2 algorithm, showing the robustness of the method.
In order to obtain a 3D visualization, the expression data
restricted to the 331 probe-sets was projected on its first 3
principal components, i.e., the components of maximum
variance. It is evident that the two classes are clearly
separated in the multidimensional space (Figure 2b). In
Table 2 we list the selected genes and the highest
frequency score associated to each of them.
Over-representation analysis using DAVID web-tool
revealed that the main GO terms in the biological process
(BP) domain include: neuronal development, brain
morphogenesis and anatomical structure development.
Thanks to the EGAN software program, that interfaces
with existing GO and literature annotation of the genes
and with canonical pathways to perform enrichment
statistics, molecular networks based on direct or indirect
gene-gene interactions were created for the list of 206
genes we identified. The most enriched pathways are
chemokine signaling, mitogen-activated protein kinase
(MAPK) signaling, T cell receptor signaling and cell
adhesion molecules (CAMs) pathways (Figure 2c).
Using the available WEB-based gene set analysis tools,
a functionally based criterion was then applied to the list
of 206 genes in order to select groups of genes that were
most represented in the tumour development pathways
and that were top-ranked in the l1l2 list. The resultant min-
imal list was composed by 19 out of 331 probe-sets, corre-
sponding to 15 loci, see Table 3. Relative functional analysis
showed that the selected genes enriched BP related to CNS
neuron differentiation, forebrain development, regulation of
metabolic process, and cell proliferation. A brief comment
of each locus is reported in Additional file 4, listing the
main protein functions for the 15 genes that significantly
discriminate infratentorial versus supratentorial LGGs.
qPCR analysis
In order to confirm and validate the results of microarray
analyses, we considered 52 samples measured with qPCR,
whose 34 samples from dataset 1 subjected to microarray
experiments and 18 samples from dataset 2, on which
Figure 2 Infratentorial vs. Supratentorial LGGs. a) Heatmap - infratentorial vs. supratentorial LGGs. Heatmap plot of the gene expression
submatrix of the 40 samples restricted to the 331 probe-sets selected by the l1l2 feature selection. The tumours are grouped according to the
lesion site (infratentorial vs. supratentorial). Each column represents a sample and each row is associated to a probe-set. The relative expression of
the probe-sets is normalized ranging from 0 (blue, under-represented) to 1 (red, over-expressed); b). This figure illustrates a 3-dimensional
visualization of the dataset restricted to the 331 selected probe-sets. The 3D representation is obtained by projecting the data submatrix onto its
3 principal components i.e. the components of maximum variance. Red circles represent the supratentorial and the blue circles the infratentorial
LGGs; c). EGAN sotware provide a hypergraph visualization showing how enriched gene sets/pathways/GO connect significant genes from LGGs
signature along with standard protein-protein interaction.
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quantification of the gene expression level for each
gene was performed according to the comparative
method 2-ΔΔCt, using the averaged ΔCt value on all
the LGG samples as tissue control (ΔCtref ). All 15
loci (represented by 19 probe-sets) were confirmed
and validated (Table 4). The qPCR confirmed that all
the 15 genes were differentially expressed between
infratentorial versus supratentorial LGGs in multivariate
analysis (RLS) (Table 4). Indeed, the Mann–Whitney test
identified 5 out of 15 genes which were also significant in
univariate analysis (Table 4). They were: aristaless related
homeobox (ARX), chemokine (C-X-C motif) ligand 14
(CXCL14), G protein-coupled receptor 17 (GPR17), LIMhomeobox 2 (LHX2) and prostaglandin D2 synthase
(PTGD2S), whose expressions resulted down-regulated in
infratentorial tumours and up-regulated in supratentorial
ones. For each sample we measured the qPCR expressions
of the 5 selected genes and we verified that the
expressions were up- and down- regulated according
to the lesion site (Figure 3a).
Next, to build a multivariate statistical model on the
qPCR data and validate the results of the microarray
analyses we applied RLS classification method. The
LOO-cross-validation error was 25%. The multivariate
model obtained with the RLS analysis was used to
classify the available samples, achieving an accuracy
of 91%. The classification results were compared to
Table 2 Infratentorial vs Supratentorial LGGs: selected genes by l1l2
Gene f.s. Gene f.s. Gene f.s. Gene f.s. Gene f.s.
ABBA1 100 KIAA2022 100 KIAA1189 98 RHOB 92 ZNF228 78
ADRBK2 100 NRGN 100 KLHDC8A 98 RORB 92 LTB4DH 75
ALK 100 PAX3 100 LRAP 98 SCG2 92 TMEPAI 75
AMMECR1 100 PCDH8 100 MAN2A1 98 SLC10A4 92 BMS1P5 72
ANKRD10 100 PCDHB16 100 NEFH 98 SNRPN 92 KIAA1967 72
APOD 100 PCNX 100 NHSL1 98 SOX4 92 KRAS 72
ARRB1 100 PDGFRA 100 NOS1 98 SPRN 92 MNDA 72
ARX 100 PKIB 100 NR4A1 98 TOB1 92 CUL4A 70
ATP6V0E1 100 PPM1E 100 PLK2 98 AKAP11 90 NRXN2 70
ATXN3 100 PPP1R9A 100 POLR2J2 98 FCF1 90 VSNL1 70
BICD1 100 PRO1073 100 POSTN 98 GFAP 90
RBM15 100 RARRES1 100 PSD3 98 GPR98 90
C1QL1 100 RASGRP1 100 RPS11 98 MAP4K4 90
CAPN3 100 RCOR1 100 SPAG9 98 RAB27B 90
CCDC76 100 RGS4 100 SPATA18 98 SHC4 90
CD24 100 RRM2 100 SPOCK1 98 VAMP1 90
CHAD 100 SDC3 100 STON2 98 CRYAB 88
CNIH3 100 SHROOM3 100 TMEM158 98 DOCK9 88
COCH 100 SLC35A3 100 TSPAN5 98 FAM149A 88
COG5 100 SMA4 100 ZC3H7A 98 FNDC3B 88
CREB5 100 SMOC1 100 ADARB1 95 FOSB 88
CTGLF1 100 SNX21 100 CAMK2N1 95 N4BP2 88
CX3CR1 100 SOX10 100 CAMKK2 95 NUCKS1 88
CXCL14 100 STMN2 100 CDC2L5 95 RPL37A 88
CYR61 100 STXBP6 100 COL22A1 95 SST 88
ENC1 100 SUSD5 100 GLTSCR2 95 ZNF226 88
EPHX1 100 TIMP4 100 GPNMB 95 GRM3 85
F2RL1 100 TMTC4 100 GRIA4 95 KIAA1919 85
FBXL3 100 TNFAIP6 100 LRRFIP1 95 PGM2L1 85
FNDC1 100 TRPM3 100 LYZ 95 PTPRC 85
FOS 100 U2AF1 100 NANOG 95 CCL4 82
FOXG1 100 ZFHX4 100 OLFM2 95 CUL2 82
FZD7 100 ZFP36 100 OPA1 95 FBXL11 82
GADD45B 100 ZNF207 100 PHCA 95 GARNL4 82
GNL3L 100 ZNF294 100 PKP4 95 LCMT2 82
GUCY1A3 100 ADRB1 98 PLEKHA2 95 TMEM132E 82
HINT3 100 ALDOC 98 PMP2 95 TYMS 82
HS3ST3B1 100 ANKRD22 98 PPP2R5C 95 GGNBP2 80
ID4 100 ATM 98 WIF1 95 IL8 80
IRX2 100 CCDC91 98 ASCL1 92 PLA2G2A 80
KIAA0101 100 CLEC4A 98 AZGP1 92 PMS2L5 80
KRIT1 100 COL9A2 98 F11R 92 S100A1 80
LHX2 100 ENPP2 98 FZD8 92 SEZ6L 80
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Table 2 Infratentorial vs Supratentorial LGGs: selected genes by l1l2 (Continued)
MBP 100 FAM107B 98 LCAT 92 ZNF423 80
MICAL2 100 FAM89A 98 LMO2 92 EPHA5 78
NAIP 100 FRMD4A 98 MIAT 92 GPBP1L1 78
NCOA3 100 GALNT13 98 NEFM 92 MCTP1 78
NEFL 100 GAS7 98 PPP1CB 92 PTPN5 78
NR2E1 100 GPR17 98 PTGD2S 92 STMN4 78
List of 206 gene symbols selected by the l1l2 procedure. For each Gene ID we report the highest frequency score. We share 14 genes, showed in bold, with the
results reported by previous studies [9,19,20].
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analysis on the microarray data (Figure 3b). Needless to
say, we could only compare the results on the sam-
ples in dataset 1 measured both with microarray and
qPCR (n = 34). 29 out of 34 (85%) were correctly
classified by both methods. The microarray and qPCR
analyses could not correctly classify 3 cases, two of
which were assigned to the right class by the qPCR
model. One sample was incorrectly classified by both
approaches hence 33 out of 34 were associated to the
right class by either method.
Microarray-based differences of infratentorial versus
supratentorial PAs
Similarly, we conducted the analysis only on 27 PAs out
of 40 LGGs (the FA was excluded), whose 17 arising in
infratentorial and 10 in supratentorial regions, see
Table 1. Thank to the application of the l1l2 selection
framework to the dataset, a list of 136 highly discrimina-
tive probe-sets corresponding to 82 genes was selected
(see Additional file 5). The system performance was
evaluated by its corresponding cross-validation error, as
low as 15.4%.
The strong discriminative power of the 136 selected
probe-sets is visualized in Figure 4a,b. As shown in
Figure 4b, the two classes of PA related to site of lesion
are clearly separated in the multidimensional space.
Again, the functional characterization of the gene signa-
ture performed with different web-tools, shows distinct
processes enriched, as following: nervous system devel-
opment, cell morphogenesis and cell adhesion, MAPK
cascade, and chemotaxis. Moreover, the main pathways
coming out are: chemokine signaling, transforming
growth factor beta (TGF-β) signaling, MAPK signaling,
Glioma, and WNT signaling pathways. The gene sig-
nature of this question is almost completely included
in the larger LGG gene signature (62 common genes),
but nineteen genes were specifically related to PA
histotype as a group (see genes reported in bold in
Additional file 5). Intriguingly, gene ontology analysis
showed that distinct genes among the 19 related to PA,
create a network within the TGF-β signaling pathway
[KEGG ID: 04350].Microarray-based differences of supratentorial tumours:
mixed glial-neuronal tumours versus PAs
Finally, the same analysis pipeline was applied to 22
supratentorial LGGs to distinguish mixed glial-neuronal
tumours (12 samples) from PAs (10 samples), see Table 1.
The l1l2 algorithm selected a list of 103 highly discrimina-
tive probe-sets corresponding to 70 genes as shown in
Additional file 6. Even in this case, the system performance
with its corresponding cross-validation error, i.e., 27%
was analyzed.
The list of 70 genes, able to discriminate mixed
glial-neuronal tumours vs. PAs (Figure 4c,d), includes
genes involved in the extracellular matrix organization,
forebrain development, and neuron differentiation such as
distal-less homeobox 1 and 2 (DLX1, DLX2), immune
response, such as hemoglobin alpha 1 and 2 (HBA1/2),
chemokine (C-X-C motif) ligand 12 (CXCL12), chemokine
(C-C motif) ligand 5 (CCL5), and metabolic proteins
(Additional file 4). Distinct pathways are enriched: toll-like
receptor signaling, focal adhesion, extracellular matrix
constituents and remodeling machinery, and extracellular
matrix (ECM) receptor interaction pathways. Interestingly,
the presence of gene family of collagen such as collagen
type I, alpha 1 and 2 (COL1A1, COL1A2), collagen type
III, alpha1 (COL3A1), collagen type V, alpha 1 (COL5A1),
and collagen type VI, alpha 2 and 3 (COL6A2, COL6A3)
are significantly represented in mixed glial-neuronal
tumours.
Discussion
A major emphasis has historically been placed on
stratifying LGGs diagnosis or therapy on the basis of
pathological and molecular genetic criteria. However,
the increasing application of molecular approaches is
transforming the way to categorize these tumours,
since it seems that histologically comparable lesions
may exhibit diverse patterns of gene expression and
genomic alterations [5-7,9,19,20]. This investigation
has focused on the identification of a specific gene
signature based on high-throughput techniques that
provide a genome-wide snapshot of LGGs with re-
spect to both distinct lesion site in the brain and
histotype.
Table 3 Molecular fingerprint of LGGs composed by the selected 15 genes
Gene/Locus Description Biological Process
FOXG1 / 14q13 forkhead box G1 GO:0007417 CNS development GO:0022008 neurogenesis
GO:0030900 forebrain development GO:0048699 generation of neurons
GO:0021954 CNS neuron development GO:0021953 CNS neuron differentiation
GO:0048666 neuron development GO:0007423 sensory organ development
GO:0043583 ear development GO:0009953 dorsal/ventral pattern formation
GO:0006355 regulation of transcription, DNA-dependent
GO:0051252 regulation of RNA metabolic process
GO:0045449 regulation of transcription
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048812 neuron projection morphogenesis
GO:0048858 cell projection morphogenesis GO:0032990 cell part morphogenesis
GO:0031175 neuron projection development
GPR17 / 2q21 G protein-coupled receptor 17 GO:0007165 signal trasduction
GO:0007186 G-protein coupled receptor protein signaling pathway
CXCL14 / 5q31 chemokine (C-X-C motif) GO:0006995 immune response GO: 0006935 chemotaxis
ligand 14 GO:0007267 cell-cell signaling GO:0007165 signal trasduction
ARX / Xp21 aristaless related homeobox GO:0007417 CNS development, GO:0022008 neurogenesis
GO:0030900 forebrain development, GO:0048699 generation of neurons
GO:0021954 CNS neuron development, GO:0021987 cerebral cortex development
GO:0021543 pallium development
GO:0006355 regulation of transcription, DNA-dependent
GO:0051252 regulation of RNA metabolic process
GO:0045449 regulation of transcription
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048812 neuron projection morphogenesis
GO:0048858 cell projection morphogenesis
GO:0032990 cell part morphogenesis
GO:0031175 neuron projection development
LHX2 / 9q33q34.1 LIM homeobox 2 GO:0007417 CNS development GO:0022008 neurogenesis
GO:0030900 forebrain development GO:0048699 generation of neurons
GO:0048666 neuron development GO:0009953 dorsal/ventral pattern formation
GO:0006355 regulation of transcription, DNA-dependent
GO:0051252 regulation of RNA metabolic process
GO:0045449 regulation of transcription
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid
GO:0048667 cell morphogenesis involved in neuron differentiation
GO:0048812 neuron projection morphogenesis
GO:0048858 cell projection morphogenesis
GO:0032990 cell part morphogenesis, GO:0031175 neuron projection development
TIMP4 / 3p25 TIMP metallopeptidase GO:0007417 CNS development GO:0009725 response to hormone stimulus
inhibitor 4 GO:0032496 response to lipopolysaccharide
GO:0034097 response to cytokine stimulus
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Table 3 Molecular fingerprint of LGGs composed by the selected 15 genes (Continued)
APOD / 3q26.2qter apolipoprotein D GO.0006629 lipid metabolic process
PTGD2S / 9q34.2-34.3 prostaglandin D2 synthase GO:0006633 fatty acid biosynthetic process
21 kDa (brain) GO:0006810 transport
SDC3 / 1pter-p22.3 syndecan 3 GO:0007155 cell adhesion
NRXN2 / 11q13 neurexin 2 GO:0007268 synaptic trasmission GO:0007269 neurotransmitter secretion
GO:0007416 synapse assembly GO:0007155 cell adhesion
SNX22 / 15q22.31 sorting nexin 22 GO:0007165 signal trasduction GO:0007154 cell comunication
ZFHX4 / 8q21.11 zinc finger homeobox 4 GO:0006355 regulation of transcription, DNA-dependent
GO:0051252 regulation of RNA metabolic process
GO:0045449 regulation of transcription
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid
GO:0015031 protein transport
SPOCK1 / 5q31 testican 1 GO:0007417 CNS development GO:0007165 signal trasduction
GO:0007155 cell adhesion
ABBA1 / 16q22.1 metastasis suppressor 1 like GO:0007165 signal trasduction
FOSB / 19q13.32 FBJ murine osteosarcoma GO:0006355 regulation of transcription, DNA-dependent
viral oncogene homolog B GO:0051252 regulation of RNA metabolic process
GO:0045449 regulation of transcription
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid
Gene annotations and GO Biological Process terms for the minimal list of 15 genes, selected for the biologically validated molecular fingerprint of LGGs related to
site of lesion (infratentorial vs supratentorial).
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expression profiles of LGGs, they are often conflicting.
Indeed, statistical methods for evaluation and interpret-
ation of microarray data are still evolving. We successfully
adopted an analysis workflow (Figure 1) able to overcome
a major criticality in high-throughput studies, that is to
find robust, reproducible and biologically sound results
[16,46]. Details of the workflow description are reported
in Additional file 1.
Brain region-specific gene signature among LGGs
Question (1) was used to assess the procedure and
represent the first example of biologically validated l1l2
framework with an independent methodology. Indeed,
this query is the one with more samples available as well
as the one already investigated in previous works [9,19].
The provided outcome from l1l2 was a list of 331 probe
sets (Additional file 3), corresponding to 206 loci, above
70% of frequency. l1l2 produces a multi-gene model and
only a multidimensional representation can correctly
visualize its strong discriminative power (Figure 2b). The
figure shows that the infratentorial tumours group is
spatially separated from the supratentorial counterpart.
Our analysis identified various interesting genes which
encode cell adhesion molecules, ECM, extracellular matrix,
lipid metabolism, CNS development, cell differentiation,
transcription regulation, and invasion-related proteins.
Unlike Potter et al. reported [21], our results are in linewith previous findings that clearly defined the exist-
ence of PA subgroups. Indeed, 14 out of 206 differentially
expressed genes (reported in bold in Table 2) were reported
by previous studies [9,19,20]. Wong and colleagues identi-
fied two subgroups of PA reporting a list of significant
differentially expressed genes involved in cell adhesion,
regulation of cell growth, cell motility, and angiogenesis
[19]. Sharma and colleagues reported differential expression
of genes playing a role in forebrain development as LHX2
and nuclear receptor subfamily 2, group E, member 1
(NR2E1), and hindbrain development as paired box gene 3
(PAX3) and iroquois homeobox protein 2 (IRX2), able to
stratify infratentorial from supratentorial PAs [9]. The
comparison with the Sharma’s data, the only comparable,
inasmuch as homologous for case selection, sample
processing and Affymetrix platform, allowed us, even
using our own statistical approach, to identify five
genes (LHX2, NR2E1, PAX3, IRX2, and zinc finger
homeobox 4, (ZFHX4) common to both analyses.
To investigate paediatric LGG development related to site
of lesion (infratentorial vs. supratentorial) [47], we next
proceeded by selecting those candidate genes that were
most represented among all the high-ranked pathways for
the validation process by using our in-house designed
qPCR systems on 52 samples (34 samples belonged to
dataset 1, while 18 samples were from dataset 2).
Finally, the list of candidates comprised 19 probe-sets
corresponding to 15 loci in total (Table 3). We validated
Table 4 qPCR expression values for the selected 15 genes
Gene name Supratentorial Infratentorial ΔCt median I. vs. S.
ΔCt 2-ΔΔCt ΔCt 2-ΔΔCt p-value
ABBA1 2.19 1.46 2.88 0.9 2.72 -
APOD −1.33 0.69 −2.46 1.6 −1.87 -
ARX 6.03 2.46 8.25 0.53 7.33 0.03
CXCL14 0.84 12.61 7.17 0.18 4.5 0.009
FOSB 4.15 0.98 3.84 1.27 4.11 -
FOXG1 4.65 0.7 3.38 1.69 4.14 -
GPR17 2.85 1.52 8.18 0.04 3.43 0.0049
LHX2 4.6 7.59 9.04 0.35 7.52 0.01
NRXN2 6.28 1.18 6.52 0.99 6.51 -
PTGD2S 1.34 1.66 5.4 0.1 2.08 0.0049
SDC3 2.9 0.94 1.79 2.03 2.81 -
SNX22 6.98 0.73 6.34 1.11 6.5 -
SPOCK1 3.99 0.88 3.06 1.69 3.81 -
TIMP4 2.62 0.92 2.42 1.05 2.48 -
ZFHX4 −0.43 0.85 −0.84 1 −0.84 -
qPCR values for dataset 1 (34 samples) and 2 (18 samples). Gene expressions were
significantly different for all listed genes by multivariate analysis (RLS). The genes in
bold are those passing the Mann–Whitney test (only its significant p-values are
reported on the right column). S: Supratentorial, I: Infratentorial.
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http://www.biomedcentral.com/1471-2407/13/387the generalization ability of the 15 gene signature by
applying a multivariate statistical model on the qPCR
data of dataset 1 (34 samples). Such multivariate
model, obtained with a RLS analysis, was used to assign
the samples to a group and the classification results were
compared to the l1l2 microarray-based model (Figure 3b).Figure 3 The best differentially expressed genes with qPCR between
expressed genes with qPCR between infratentorial and supratentorial LGGs
selected with univariate Mann–Whitney test; b) in this plot we show the co
RLS classification function for each sample measured by both qPCR and m
while positives are the supratentorial ones. The blue circles correspond to t
misclassified samples by qPCR. The green dots are the misclassified sampleThe two independent methods have good performances,
being able to associate 33 out of 34 samples to the right
class. Moreover, 5 out of 15 genes emerged from the uni-
variate Mann–Whitney test on the qPCR data, confirming
and enhancing the LGG differences in infratentorial as
compared with supratentorial regions, see Table 4 and
Figure 3a. As shown in Figure 3a, a group of 4 genes
(ARX, GPR17, LHX2 and CXCL14) well stratified LGGs
between infratentorial and supratentorial tumours. ARX is
a homeobox-containing gene expressed during develop-
ment. This gene is involved in CNS development and in
cell proliferation in forebrain [GO:0021846]. Mutations in
this gene cause X-linked mental retardation and epilepsy.
To the best of our knowledge, ARX was never associated
with LGGs. GPR17 is a G-protein involved in signal
transduction [GO:0007165]. LHX2 is downregulated in
infratentorial tumours as already reported [9]. CXCL14 is
a chemokine associated with tumour development
[GO:0006995], and PTDG2S whose functions are associ-
ated to lipid metabolism [GO:0006633], might be involved
in controlling the proliferation rate of LGGs.
Additionally, the predominant terms related to pathways
consisted of MAPK signaling pathway, containing at least
12 genes, followed by chemokine signaling pathway with 8
genes enriched. These findings reinforce the observations
of several consecutive articles about aberrant activation of
the mitogen-activated protein kinase (MAPK) pathway in
LGGs [48]. The identification of a brain region-specific
gene signature suggests that LGGs at different sites
may be distinct in terms of biological properties and
tumorigenesis despite the same histology. KIAA1549:infratentorial and supratentorial LGGs. a) the best differentially
. Relative gene expression for the best 5 differentially expressed genes
mparison between the microarray and the values of the estimated
icroarray. The negative values are assigned to the infratentorial site,
he correctly classified cases by qPCR. The red circles indicate the
s by the microarray model.
Figure 4 Molecular fingerprinting sub-classify infratentorial from supratentorial PAs as well as separate mixed glial-neuronal tumours
from PAs. a) heatmap - infratentorial vs. supratentorial PAs. Heatmap plot of the gene expression submatrix of the 27 PAs restricted to the 136
probesets selected by the l1l2 feature selection. The tumours are grouped according to the lesion site (infratentorial vs. supratentorial). Each
column represents a sample and each row is associated to a probe-set. The relative expression of the probe-sets is normalized ranging from 0
(blue, under-represented) to 1 (red, over-expressed), b) This figure illustrates a 3-dimensional visualization of the dataset restricted to the 136
selected probe-sets. The 3D representation is obtained by projecting the data submatrix onto its 3 principal components i.e. the components of
maximum variance. Red circles represent the supratentorial and the blue circles the infratentorial PAs; c) This figure illustrates a 3D projection of
the dataset restricted to the 103 selected probe-sets for the supratentorial tumours: mixed glial-neuronal tumours vs. PAs. The 3D representation
is obtained by projecting the data submatrix onto its 3 principal components i.e. the components of maximum variance. Red circles represent the
PAs and the blue circles the mixed glial-neuronal tumours; d) Heatmap plot of the gene expression submatrix of the 22 supratentorial tumours
restricted to the 103 probe-sets selected by the l1l2 feature selection. The tumours are grouped according to the histotype (mixed glial-neuronal
tumours vs. PAs) Each column represents a sample and each row is associated to a probe-set. The relative expression of the probe-sets is
normalized ranging from 0 (blue, under-represented) to 1 (red, over-expressed).
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we found the gene fusion slightly more frequent in
infratentorial (38.5%) versus supratentorial (25%) tumours,
while we didn’t note any difference for BRAF V600E
mutation. Moreover, we did not identify significantly
improved progression-free survival in tumours with
gene-fusions or BRAF V600E mutation.Identification of a subgroup of 19 genes specifically
related with PA histotype
Next, to molecularly characterize PA able to distinguish
infratentorial versus supratentorial, l1l2 analysis were
conducted only on 27 PAs out of 37 LGGs, whose
17 arising in infratentorial and 10 in supratentorial
regions, see Table 1. A gene signature of 82 genes
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supratentorial versus infratentorial regions (Figures 4a,b).
Significant biological processes represented include GO
terms of nervous system development, cell morphogenesis,
cell differentiation and cell adhesion, MAPKKK cascade,
chemotaxis, and regulation of neurogenesis. We found that,
together with ARX, forkhead box G1 (FOXG1) was strongly
represented in PA. FOXG1 is an oncogenic transformer
which could play an important role in controlling both
cell proliferation and forebrain cell differentiation in
PA [21,49-51].
Through the comparison of gene lists between LGG
and PA, we found 19 genes specifically related with PA
histotype as a group (genes in bold in Additional file 5).
The functional analysis showed that several genes create
a network within the (TGF-β)-signaling pathway. This
pathway possess a dual role in oncogenesis. In some tumour
types, i.e., in high-grade gliomas, TGF-beta becomes an
oncogenic factor, while it is also considered a tumour
suppressor factor in normal epithelial cells and astrocytes.
Moreover, noncanonical TGF-beta signaling pathways
interact, through RSmads molecules, with MAPK signaling
pathway [52]. Thanks to this interaction, it is likely to
assume an active involvement of TGF-beta signaling
pathway in the PA development.
Our analysis shows a strong difference between
supratentorial and infratentorial PAs. In fact, cerebellar
PAs, corresponding to the classical description of the
biphasic tumour with compact areas with piloid cells
and Rosenthal fibers and microcistic areas with granular
eosinophilic bodies [3], seem to be defined by a specific
gene signature versus supratentorial PAs. Therefore, this
molecular fingerprint is able to better sub-classify such a
morphologically heterogeneous tumours.
Neurogenesis, cell motility and cell growth genes
dichotomize mixed glial-neuronal tumours versus PAs
Finally, the analysis on 22 supratentorial LGGs identified a
list of 70 genes (see Additional file 6) able to dichotomize
mixed glial-neuronal tumours versus PAs (Figure 4c,d).
The signature consists of genes encoding adhesion,
ECM-receptor interaction, matrix extracellular organization,
neurogenesis, immune response, and metabolic proteins.
Several genes are components of collagen gene family
whose functions are associated with extracellular matrix
(ECM) reorganization. Intriguingly, changes in expression
of genes controlling neurogenesis (DLX1, DLX2), cell
growth such as insulin-like growth factor 2 (IGF2), insulin-
like growth factor binding protein 6 (IGFBP6) and latent
transforming growth factor beta binding protein (LTBP2),
cell motility such as l1 cell adhesion molecule (L1CAM),
COL3A1 and integrin, alpha 8 (ITGA8), and interactions
with the surrounding environment such as lumican (LUM),
COL1A1, COL6A3 and periostin, osteoblast specific factor(POSTN) appear to be linked to the presence of neuronal
cell component.
Because of their rare occurrence, little is yet known
about the molecular pathology of mixed glial-neuronal
neoplasms and the cytogenetic and molecular genetic
studies reported are very few [53-55]. Our findings show
the complexity and vitality of these tumours, shedding
some light on features such their richness in connective
tissue and, they point to some interesting candidate genes
(i.e., DLX1, DLX2) worth further investigations that could
help the pathologists in the differential diagnosis.
From a biological point of view, it is remarkable that the
mixed glial-neuronal tumours are strikingly separated from
PAs, allowing us to look differently at mixed glial-neuronal
tumours in which, generally, the glial component catches
the attention of the pathologists and contributes to grading.
Our findings, indeed, shed some light on the biological
complexity of the mixed glial-neuronal tumours, still poorly
known. It remains to be established if mixed glial-neuronal
tumours differ from PAs because of their ganglion-like
component or because of their glial one or both. What
seems indubitable is that the ganglion cell component is
not a bystander. Future functional studies are needed to
evaluate these targets in paediatric mixed glial-neuronal
tumours versus PAs but evidence supports a role for these
gene candidates in tumorigenesis.
Conclusion
The identification of a brain region-specific gene signature
suggested that LGGs at different sites may be distinct in
terms of biological properties and tumorigenesis. The
success of our methodology carries implications for
improving the diagnosis and possibly prognosis of LGGs.
The method efficiently finds and ranks genes that can
distinguish one histotype from another. In addition, we
performed clustering and classification of GO categories
and possibly altered pathways on the basis of gene
expression in infratentorial versus supratentorial LGGs,
in particular in the PAs, and among supratentorial
tumours, in mixed glial-neuronal tumours versus PAs.
The analyses reinforce previous observations about
aberrant activation of the mitogen-activated protein
kinase (MAPK) pathway in LGGs but, still point to an
active involvement of TGF-β signaling pathway in the PA
development and, emphasize some interesting candidate
genes worth further investigations for the mixed glial-
neuronal tumours. Considering the high clinical and
biological relevance of the disease, as these tumours are
detrimental to children, and since the genetic background
of paediatric glial tumours is still unsatisfied, this methodo-
logical work could mark the starting line. A genotype-
phenotype correlation of LGGs is instrumental to improve
classification and differential diagnosis. Impact of molecular
classification will likely change how LGGs are both
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vides a novel global view of the molecular differences be-
tween infratentorial and supratentorial LGGs.
Further investigation and validation by experiments
should be targeted to the exploration of a deeper
genotype-phenotype correlation in those LGG cases who
undergo malignant transformation.Additional files
Additional file 1: Workflow for high-throughput gene-expression
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